Low-molecular-weight heparin modulates vein wall fibrotic response in a plasminogen activator inhibitor 1-dependent manner

Journal of Vascular Surgery: Venous and Lymphatic Disorders

Volumn 2, Issue 4, 2014, Pages 441-450.e1

  Obi, Andrea T ^a   Diaz, Jose A ^a   Ballard Lipka, Nicole L ^a   Roelofs, Karen J ^a   Farris, Diana M ^a   Lawrence, Daniel A ^b   Henke, Peter K ^a,c   Wakefield, Thomas W ^a  

^a Section of Vascular Surgery   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; GELATINASE A; INTERLEUKIN 13; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE RESPONSE; DEEP VEIN THROMBOSIS; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRINOLYSIS; GENE DELETION; IMMUNOCHEMISTRY; MONOCYTE; MOUSE; NONHUMAN; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; VASCULAR FIBROSIS; VEIN WALL; VEIN WALL FIBROSIS; WILD TYPE; ZYMOGRAPHY;

EID: 84908066179     PISSN: 2213333X     EISSN: 22133348     Source Type: Journal    
DOI: 10.1016/j.jvsv.2014.02.004     Document Type: Conference Paper

References (40)

1. A.A. Ashrani, and J.A. Heit Incidence and cost burden of post-thrombotic syndrome J Thromb Thrombolysis 28 2009 465 476
2. M.J. Baldwin, H.M. Moore, N. Rudarakanchana, M. Gohel, and A.H. Davies Post-thrombotic syndrome: a clinical review J Thromb Haemost 11 2013 795 805
3. J.J. Bergan, G.W. Schmid-Schonbein, P.D. Smith, A.N. Nicolaides, M.R. Boisseau, and B. Eklof Chronic venous disease N Engl J Med 355 2006 488 498
4. C. Kearon, E.A. Akl, A.J. Comerota, P. Prandoni, H. Bounameaux, and S.Z. Goldhaber Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2012 e419S e494S
5. S.R. Kahn, C. Kearon, J.A. Julian, B. Mackinnon, M.J. Kovacs, and P. Wells Predictors of the post-thrombotic syndrome during long-term treatment of proximal deep vein thrombosis J Thromb Haemost 3 2005 718 723
6. C.J. van Dongen, P. Prandoni, M. Frulla, A. Marchiori, M.H. Prins, and B.A. Hutten Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome J Thromb Haemost 3 2005 939 942
7. R.D. Hull, G.F. Pineo, R. Brant, J. Liang, R. Cook, and S. Solymoss Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome Am J Med 122 2009 762 769.e3
8. R.D. Hull, J. Liang, and T. Merali Effect of long-term LMWH on post-thrombotic syndrome in patients with iliac/noniliac venous thrombosis: a subanalysis from the home-LITE study Clin Appl Thromb Hemost 19 2013 476 481
9. B.M. Wojcik, S.K. Wrobleski, A.E. Hawley, T.W. Wakefield, D.D. Myers Jr., and J.A. Diaz Interleukin-6: a potential target for post-thrombotic syndrome Ann Vasc Surg 25 2011 229 239
10. J.A. Diaz, N.E. Ballard-Lipka, D.M. Farris, A.E. Hawley, S.K. Wrobleski, and D.D. Myers Impaired fibrinolytic system in ApoE gene-deleted mice with hyperlipidemia augments deep vein thrombosis J Vasc Surg 55 2012 815 822
11. T. Enden, N.E. Klow, L. Sandvik, C.E. Slagsvold, W. Ghanima, and G. Hafsahl Catheter-directed thrombolysis vs. anticoagulant therapy alone in deep vein thrombosis: results of an open randomized, controlled trial reporting on short-term patency J Thromb Haemost 7 2009 1268 1275
12. R.C. Becker, K.W. Mahaffey, H. Yang, A.J. Marian, M.I. Furman, and A. Michael Lincoff Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome J Thromb Thrombolysis 31 2011 146 153
13. J.F. Baldwin, V. Sood, M.A. Elfline, C.E. Luke, N.A. Dewyer, and J.A. Diaz The role of urokinase plasminogen activator and plasmin activator inhibitor-1 on vein wall remodeling in experimental deep vein thrombosis J Vasc Surg 56 2012 1089 1097
14. P. Bacher, D. Welzel, O. Iqbal, D. Hoppensteadt, D. Callas, and J.M. Walenga The thrombolytic potency of LMW-heparin compared to urokinase in a rabbit jugular vein clot lysis model Thromb Res 66 1992 151 158
15. A.K. Ghosh, and D.E. Vaughan PAI-1 in tissue fibrosis J Cell Physiol 227 2012 493 507
16. K.B. Deatrick, J.L. Eliason, E.M. Lynch, A.J. Moore, N.A. Dewyer, and M.R. Varma Vein wall remodeling after deep vein thrombosis involves matrix metalloproteinases and late fibrosis in a mouse model J Vasc Surg 42 2005 140 148
17. K.B. Deatrick, C.E. Luke, M.A. Elfline, V. Sood, J. Baldwin, and G.R. Upchurch Jr. The effect of matrix metalloproteinase 2 and matrix metalloproteinase 2/9 deletion in experimental post-thrombotic vein wall remodeling J Vasc Surg 58 2013 1375 1384
18. P.K. Henke, A. Varga, S. De, C.B. Deatrick, J. Eliason, and D.A. Arenberg Deep vein thrombosis resolution is modulated by monocyte CXCR2-mediated activity in a mouse model Arterioscler Thromb Vasc Biol 24 2004 1130 1137
19. K.A. Patterson, X. Zhang, S.K. Wrobleski, A.E. Hawley, D.A. Lawrence, and T.W. Wakefield Rosuvastatin reduced deep vein thrombosis in ApoE gene deleted mice with hyperlipidemia through non-lipid lowering effects Thromb Res 131 2013 268 276
20. P.K. Henke, M.R. Varma, D.K. Moaveni, N.A. Dewyer, A.J. Moore, and E.M. Lynch Fibrotic injury after experimental deep vein thrombosis is determined by the mechanism of thrombogenesis Thromb Haemost 98 2007 1045 1055
21. P.K. Henke, M. Mitsuya, C.E. Luke, M.A. Elfline, J.F. Baldwin, and K.B. Deatrick Toll-like receptor 9 signaling is critical for early experimental deep vein thrombosis resolution Arterioscler Thromb Vasc Biol 31 2011 43 49
22. P.K. Henke, C.G. Pearce, D.M. Moaveni, A.J. Moore, E.M. Lynch, and C. Longo Targeted deletion of CCR2 impairs deep vein thombosis resolution in a mouse model J Immunol 177 2006 3388 3397
23. G.B. Gervasi, C. Farina, R. Catalani, C. Bartoli, and M. Baldacci "In vitro" fibrinolytic activity of a new low molecular weight heparan sulfate Thromb Res 59 1990 931 939
24. A. Markel, R.A. Manzo, R.O. Bergelin, and D.E. Strandness Jr. Valvular reflux after deep vein thrombosis: incidence and time of occurrence J Vasc Surg 15 1992 377 382 discussion: 383-4
25. K.B. Deatrick, M. Elfline, N. Baker, C.E. Luke, S. Blackburn, and C. Stabler Postthrombotic vein wall remodeling: preliminary observations J Vasc Surg 53 2011 139 146
26. A. Sica, P. Larghi, A. Mancino, L. Rubino, C. Porta, and M.G. Totaro Macrophage polarization in tumour progression Semin Cancer Biol 18 2008 349 355
27. R. Solberg, T. Scholz, V. Videm, C. Okkenhaug, and A.O. Aasen Heparin coating reduces cell activation and mediator release in an in vitro venovenous bypass model for liver transplantation Transpl Int 11 1998 252 258
28. J.E. Rectenwald, K.B. Deatrick, P. Sukheepod, E.M. Lynch, A.J. Moore, and D.M. Moaveni Experimental pulmonary embolism: effects of the thrombus and attenuation of pulmonary artery injury by low-molecular-weight heparin J Vasc Surg 43 2006 800 808
29. S.R. Kahn, I. Shrier, J.A. Julian, T. Ducruet, L. Arsenault, and M.J. Miron Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis Ann Intern Med 149 2008 698 707
30. A.J. Comerota, R.C. Throm, S.D. Mathias, S. Haughton, and M. Mewissen Catheter-directed thrombolysis for iliofemoral deep venous thrombosis improves health-related quality of life J Vasc Surg 32 2000 130 137
31. N.K. Grewal, J.T. Martinez, L. Andrews, and A.J. Comerota Quantity of clot lysed after catheter-directed thrombolysis for iliofemoral deep venous thrombosis correlates with postthrombotic morbidity J Vasc Surg 51 2010 1209 1214
32. D.D. Myers Jr., P.K. Henke, S.K. Wrobleski, A.E. Hawley, D.M. Farris, and A.M. Chapman P-selectin inhibition enhances thrombus resolution and decreases vein wall fibrosis in a rat model J Vasc Surg 36 2002 928 938
33. D.K. Moaveni, E.M. Lynch, C. Luke, V. Sood, G.R. Upchurch, and T.W. Wakefield Vein wall re-endothelialization after deep vein thrombosis is improved with low-molecular-weight heparin J Vasc Surg 47 2008 616 624
34. R. Nakamura, K. Umemura, H. Hashimmoto, and T. Urano Less pronounced enhancement of thrombin-dependent inactivation of plasminogen activator inhibitor type 1 by low molecular weight heparin compared with unfractionated heparin Thromb Haemost 95 2006 637 642
35. E.P. Bianchini, R.N. Pike, and B.F. Le Bonniec The elusive role of the potential factor X cation-binding exosite-1 in substrate and inhibitor interactions J Biol Chem 279 2004 3671 3679
36. P.K. Henke, M.R. Varma, K.B. Deatrick, N.A. Dewyer, E.M. Lynch, and A.J. Moore Neutrophils modulate post-thrombotic vein wall remodeling but not thrombus neovascularization Thromb Haemost 95 2006 272 281
37. L.J. Downing, R.M. Strieter, A.M. Kadell, C.A. Wilke, L.J. Greenfield, and T.W. Wakefield Low-dose low-molecular-weight heparin is anti-inflammatory during venous thrombosis J Vasc Surg 28 1998 848 854
38. A.B. Fogo Renal fibrosis: not just PAI-1 in the sky J Clin Invest 112 2003 326 328
39. P. Thanaporn, D.D. Myers, S.K. Wrobleski, A.E. Hawley, D.M. Farris, and T.W. Wakefield P-selectin inhibition decreases post-thrombotic vein wall fibrosis in a rat model Surgery 134 2003 365 371
40. J.A. Carr, and J.S. Cho Low molecular weight heparin suppresses tumor necrosis factor expression from deep vein thrombosis Ann Vasc Surg 21 2007 50 55